Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
FDA endorses Merck's Keytruda for the 1st time in ovarian cancer
Thirteen years after the FDA first blessed Keytruda for melanoma, the agency has approved the PD-1 superstar for a certain type of ovarian cancer.
Kevin Dunleavy
Feb 11, 2026 10:04am
Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop
Jan 29, 2026 11:23am
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
ESMO: Merck lays out Keytruda's landmark win in ovarian cancer
Oct 18, 2025 10:30am
Merck scores FDA approval for subcutaneous Keytruda
Sep 19, 2025 4:54pm
